

September 08, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings

Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Analyst / Institutional Investor meetings to be conducted as follows:

Date	Analyst/Institutional Investors/Event	Venue	Type of Meeting	Group / One-on-one
11th - 12th September, 2025	Meetings in Singapore	Singapore	Physical	One-on-One

The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on the part of Investor / Company.

We request you to take this intimation on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Limited

Glenmark House, B. D. Sawant Marg, Andheri (E), Mumbai 400 099, India

T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com